Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Briacell Therapeutics Corp. T.BCT

Alternate Symbol(s):  BCTX | BCTXW

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II... see more

Recent & Breaking News (TSX:BCT)

BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants

GlobeNewswire September 9, 2021

Marc Lustig joins BriaCell Therapeutics’ (TSXV:BCT) Board of Directors

John Ballem  September 1, 2021

BriaCell Therapeutics Appoints Marc Lustig to its Board of Directors

GlobeNewswire September 1, 2021

BriaCell to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

GlobeNewswire August 23, 2021

BriaCell (TSXV:BCT) and ImaginAb to evaluate advanced breast cancer with immunotherapy imaging technology

Jocelyn Aspa August 19, 2021

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer

GlobeNewswire August 19, 2021

BriaCell Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

GlobeNewswire July 14, 2021

BriaCell to Present at Three Upcoming Investor Conferences

GlobeNewswire July 12, 2021

BriaCell (TSXV:BCT) expands breast cancer technology

Trevor Abes  June 16, 2021

BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

GlobeNewswire June 16, 2021

BriaCell Therapeutics (TSXV:BCT) announces proceeds of US$12.88 million from warrant exercises

Brieanna McCutcheon  June 10, 2021

BriaCell Therapeutics Announces Proceeds of US$12.88 Million from Warrant Exercises

GlobeNewswire June 10, 2021

BriaCell to Host Corporate and Clinical Update Conference Call Wednesday, June 16, 2021 at 4:30 p.m. ET

GlobeNewswire June 9, 2021

BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement

GlobeNewswire June 7, 2021

BriaCell Therapeutics (TSXV:BCT) announces US$27.2 million private placement

John Ballem  June 3, 2021

IIROC Trading Resumption - BCT

Canada NewsWire June 3, 2021

BriaCell Therapeutics Corp. Announces US$27.2 Million Private Placement

GlobeNewswire June 3, 2021

IIROC Trading Halt - BCT

Canada NewsWire June 3, 2021

BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of 'Eye-Bulging' Tumor

GlobeNewswire June 2, 2021

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

GlobeNewswire May 19, 2021